scispace - formally typeset
Journal ArticleDOI

Future directions for peptide therapeutics development.

Allan Kaspar, +1 more
- 01 Sep 2013 - 
- Vol. 18, Iss: 17, pp 807-817
Reads0
Chats0
TLDR
An overview of the peptide therapeutics pipeline is provided, including therapeutic area and molecular targets, with a focus on glucagon-like peptide 1 receptor agonists, and areas for potential expansion are profiled.
About
This article is published in Drug Discovery Today.The article was published on 2013-09-01. It has received 614 citations till now.

read more

Citations
More filters
Journal ArticleDOI

Peptide therapeutics: current status and future directions.

TL;DR: The current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development are discussed.
Journal ArticleDOI

Coronavirus envelope protein: current knowledge

TL;DR: Data shows that E is involved in critical aspects of the viral life cycle and that CoVs lacking E make promising vaccine candidates, which can aid in the production of effective anti-coronaviral agents for both human CoVs and enzootic CoVs.
Journal ArticleDOI

The Current State of Peptide Drug Discovery: Back to the Future?

TL;DR: An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been critical to the discovery, design, and subsequent development of novel therapeutics.
Journal ArticleDOI

Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes

TL;DR: A new classification of peptidomimetics (classes A–D) is introduced that enables a clear assignment of available approaches for the structure-based design of PPI inhibitors through stabilizing or mimicking turns, β-sheets, and helices.
Journal ArticleDOI

Advances in Fmoc solid‐phase peptide synthesis

TL;DR: The number of synthetic peptides entering clinical trials has grown continuously over the last decade, and recent advances in the Fmoc SPPS technology are a response to the growing demand from medicinal chemistry and pharmacology.
References
More filters
Journal ArticleDOI

Glucagon-like peptide-1 7-36: a physiological incretin in man.

TL;DR: The observation of greatly increased postprandial plasma GLP-1 7-36 levels in patients with postgastrectomy dumping syndrome suggests that it may mediate the hyperinsulinaemia and reactive hypoglycaemia of this disorder.
Journal ArticleDOI

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

TL;DR: This study shows NN2211 has a pharmacokinetic profile supporting a daily dose in human beings, but also that subjects treated with NN 2211 rather than placebo, had a higher incidence of adverse events, most notably dizziness and adverse events related to the gastrointestinal system.
Journal ArticleDOI

Probing the alpha-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis.

TL;DR: Detailed all‐atom molecular dynamics simulations are used to study a series of stapled α‐helical peptides and find significant variation in local structural flexibility of the peptides with the position of the linker, which appears to be more closely related to the observed differences in activity than the absolute α‐ Helical stability.
Related Papers (5)